We are live on ! Find out more
SION

Sionna Therapeutics

6.88 USD
-1.38
16.71%
At close Updated Sep 15, 4:00 PM EDT
Pre-market
After hours
6.95
+0.07
1.02%
1 day
-16.71%
5 days
-5.36%
1 month
16.41%
3 months
-80.89%
6 months
-81.49%
Year to date
-82.45%
1 year
-69.16%
5 years
-72.48%
10 years
-72.48%
 

About: Sionna Therapeutics Inc is a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein to deliver clinically meaningful benefits to CF patients. CF is a progressive and life-threatening genetic disease caused by inherited mutations in the CFTR gene, which heads to insufficient CFTR function. The Company is managed as one operating segment focused on the research and development of cystic fibrosis therapies.

Employees: 59

News

Positive
Neutral
Negative
Sentiment 3-Months
Positive 2.5%
Neutral 87.5%
Negative 10%
Neutral
Seeking Alpha
11 hours ago
Sionna Therapeutics, Inc. (SION) Discusses Post-Hoc Analysis of PreciSION CF Trial and Advancement of Dual Combination Program Transcript
Sionna Therapeutics, Inc. (SION) Discusses Post-Hoc Analysis of PreciSION CF Trial and Advancement of Dual Combination Program Transcript
Sionna Therapeutics, Inc. (SION) Discusses Post-Hoc Analysis of PreciSION CF Trial and Advancement of Dual Combination Program Transcript
Neutral
GlobeNewsWire
1 day ago
Sionna Therapeutics Announces Plans to Advance SION-451 + SION-2222 Dual Combination into Phase 2a Proof-of-Concept Trial
Post hoc analyses of SION-719 PreciSION CF subset showed a mean placebo-adjusted sweat chloride reduction of up to -8.6 mmol/L consistent with NBD1 biological activity
Sionna Therapeutics Announces Plans to Advance SION-451 + SION-2222 Dual Combination into Phase 2a Proof-of-Concept Trial
Neutral
PRNewsWire
5 days ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sionna Therapeutics, Inc. - SION
NEW YORK, Sept. 10, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Sionna Therapeutics, Inc. ("Sionna" or the "Company") (NASDAQ: SION).
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sionna Therapeutics, Inc. - SION
Neutral
GlobeNewsWire
7 days ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sionna Therapeutics, Inc. - SION
NEW YORK, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Sionna Therapeutics, Inc. (“Sionna” or the “Company”) (NASDAQ: SION).  Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sionna Therapeutics, Inc. - SION
Neutral
PRNewsWire
12 days ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sionna Therapeutics, Inc. - SION
NEW YORK, Sept. 3, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Sionna Therapeutics, Inc. ("Sionna" or the "Company") (NASDAQ: SION).
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sionna Therapeutics, Inc. - SION
Neutral
GlobeNewsWire
13 days ago
SIONNA THERAPEUTICS INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Sionna Therapeutics Inc on Behalf of Sionna Therapeutics Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C.  Litigation Partner  Brandon Walker  Encourages Investors Who Suffered Losses In Sionna Therapeutics (SION) To Contact Him Directly To Discuss Their Options
SIONNA THERAPEUTICS INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Sionna Therapeutics Inc on Behalf of Sionna Therapeutics Stockholders and Encourages Investors to Contact the Firm
Neutral
GlobeNewsWire
14 days ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sionna Therapeutics, Inc. - SION
NEW YORK, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Sionna Therapeutics, Inc. (“Sionna” or the “Company”) (NASDAQ: SION).  Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sionna Therapeutics, Inc. - SION
Neutral
GlobeNewsWire
15 days ago
SION INVESTIGATION: Investigation Launched into Sionna Therapeutics, Inc., Robbins Geller Rudman & Dowd LLP Attorneys Encourage Investors and Potential Witnesses to Contact Law Firm
SAN DIEGO, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving Sionna Therapeutics, Inc. (NASDAQ: SION). If you have any information that could assist in the Sionna Therapeutics investigation or if you are a Sionna Therapeutics investor who suffered a loss and would like to learn more, you can provide your information here: https://www.rgrdlaw.com/cases-sionna-therapeutics-inc-investigation-sion.html You can also contact attorneys Ken Dolitsky or Michael Albert of Robbins Geller by calling 800/851-7783 or via e-mail at [email protected].
SION INVESTIGATION: Investigation Launched into Sionna Therapeutics, Inc., Robbins Geller Rudman & Dowd LLP Attorneys Encourage Investors and Potential Witnesses to Contact Law Firm
Neutral
PRNewsWire
19 days ago
INVESTIGATION ALERT: Investigation Launched into Sionna Therapeutics, Inc., Robbins Geller Rudman & Dowd LLP Attorneys Encourage Investors and Potential Witnesses to Contact Law Firm - SION
SAN DIEGO, Aug. 27, 2026 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP  is investigating potential violations of United States federal securities laws involving Sionna Therapeutics, Inc. (NASDAQ: SION). If you any have information that could assist in the Sionna Therapeutics investigation or if you are a Sionna Therapeutics investor who suffered a loss and would like to learn more, you can provide your information here: https://www.rgrdlaw.com/cases-sionna-therapeutics-inc-investigation-sion.html You can also contact attorneys Ken Dolitsky or Michael Albert of Robbins Geller by calling 800/851-7783 or via e-mail at [email protected].
INVESTIGATION ALERT: Investigation Launched into Sionna Therapeutics, Inc., Robbins Geller Rudman & Dowd LLP Attorneys Encourage Investors and Potential Witnesses to Contact Law Firm - SION
Neutral
PRNewsWire
19 days ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sionna Therapeutics, Inc. - SION
NEW YORK, Aug. 27, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Sionna Therapeutics, Inc. ("Sionna" or the "Company") (NASDAQ: SION). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sionna Therapeutics, Inc. - SION
Price charts implemented using Lightweight Charts™